US-based clinical-stage pharmaceutical company SpineThera has signed a know-how partnership agreement with Mayo Clinic, a not-for-profit academic medical centre.
The collaboration aims to develop long-acting injectable drugs to improve treatment outcomes for individuals with substance abuse disorders.
SpineThera is engaged in developing long-acting injectable drugs using its patented micro-suspension platform technology.
Its micro-suspension platform provides months-long sustained release of the active pharmaceutical ingredient with superior injectability at ultra-high concentrations.
The collaboration will be led by SpineThera CEO Jeff Missling and Mayo Clinic addiction medicine chair Tyler Oesterle.
Missling said: “SpineThera’s novel, long-acting injectable technology has potential in multiple therapeutic areas. We are honoured to move strategically into substance abuse disorder treatment through this collaboration.
“Despite multiple approved medications for the treatment of opioid use disorder, we are still losing too many people to this crisis every day and seek to make a difference through our contributions.”
According to SpineThera, the opioid crisis remains a significant public health crisis, and it impacts millions of people across the world.
There is a need to develop treatments that improve outcomes, increase patient access to supervised treatment and reduce the risk associated with existing treatments.
SpineThera is committed to addressing this healthcare challenge and improving the lives of individuals affected by substance abuse disorders.
The collaboration will leverage SpineThera’s long-acting injectable technology and Mayo Clinic’s expertise in addiction medicine, to develop effective and accessible treatment options.
Mayo Clinic has a financial interest in the technology and will use any revenue generated through the collaboration to support its not-for-profit mission in patient care and research.
